skyrizi
abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosoppressori - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
skyrizi 75 mg lnjektionslösung in einer fertigspritze
abbvie ag - risankizumabum - lnjektionslösung in einer fertigspritze - lösung: risankizumabum 75.0 mg, sorbitolum 34 mg, dinatrii succinas hexahydricus corresp. natrium 0.149 mg, natrium 0.149 mg, acidum succinicum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 0.83 ml. tela cum: alcohol isopropylicus. - plaque-psoriasis bei erwachsenen, psoriasis-arthritis - biotechnologika
skyrizi 150 mg lnjektionslösung in einer fertigspritze
abbvie ag - risankizumabum - lnjektionslösung in einer fertigspritze - risankizumabum 150 mg, natrii acetas trihydricus corresp. natrium 0.209 mg, acidum aceticum glaciale, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - plaque-psoriasis bei erwachsenen, psoriasis-arthritis - biotechnologika
skyrizi 150mg soluzione iniettabile in penna preriempita
abbvie ag - risankizumabum - soluzione iniettabile in penna preriempita - risankizumabum 150 mg, natrii acetas trihydricus corresp. natrium 0.209 mg, acidum aceticum glaciale, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 1 ml. - plaque-psoriasis bei erwachsenen; psoriasis-arthritis - biotechnologika
skyrizi 360 mg injektionslösung in einer patrone für ein dosiergerät
abbvie ag - risankizumabum - injektionslösung in einer patrone für ein dosiergerät - risankizumabum 360 mg, natrii acetas trihydricus corresp. natrium 0.5 mg, acidum aceticum glaciale, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 2.4 ml. - morbus crohn bei erwachsenen - biotechnologika
skyrizi 600 mg/10 ml concentrato per soluzione per infusione
abbvie ag - risankizumabum - concentrato per soluzione per infusione - risankizumabum 600 mg, natrii acetas trihydricus corresp. natrium 2.09 mg, acidum aceticum glaciale, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 10 ml. - morbus crohn bei erwachsenen - biotechnologika